Literature DB >> 8258236

One year treatment with low dose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors.

A Spadaro1, V Riccieri, A Sili Scavalli, E Taccari, A Zoppini.   

Abstract

We evaluated the effect of a one-year treatment of low dose methotrexate (MTX) on class specific rheumatoid factors in 27 patients with rheumatoid arthritis (RA). Enzyme-linked immunosorbent assay (ELISA) showed after 6 and 12 months a significant reduction of IgM-RF, IgA-RF and IgG-RF levels from the baseline values. During MTX treatment, changes of each RF isotype were not correlated with any other isotype and its corresponding immunoglobulin changes. Moreover, immunological changes were not related to the improvement of clinical parameters. Our results showed that low dose MTX can specifically affect levels of RF isotypes, which are involved in the immune pathogenesis of RA.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8258236     DOI： 10.1007/bf02231579

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  25 in total

1.  Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate.

Authors:  G W Cannon; J C Reading; J R Ward; L J Blonquist; L B Collette
Journal:  Scand J Rheumatol       Date:  1990       Impact factor: 3.641

2.  Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels.

Authors:  R J Winchester; V Agnello; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1970-05       Impact factor: 4.330

3.  Gold and penicillamine: a proposed mode of action in rheumatoid arthritis, based on synovial fluid analysis.

Authors:  M H Pritchard; G Nuki
Journal:  Ann Rheum Dis       Date:  1978-12       Impact factor: 19.103

4.  Use of monoclonal antibodies and F(ab')2 enzyme conjugates in ELISA for IgM, IgA and IgG rheumatoid factors.

Authors:  I Teitsson; H Valdimarsson
Journal:  J Immunol Methods       Date:  1984-07-06       Impact factor: 2.303

5.  The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers.

Authors:  N L Gottlieb; I M Kiem; N S Penneys; D R Schultz
Journal:  J Lab Clin Med       Date:  1975-12

6.  Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial.

Authors:  H Hamdy; R J McKendry; E Mierins; J A Liver
Journal:  Arthritis Rheum       Date:  1987-04

7.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

Authors:  J M Kremer; J K Lee
Journal:  Arthritis Rheum       Date:  1986-07

Review 8.  IgG rheumatoid factors and self-association of these antibodies.

Authors:  M Mannik; F A Nardella
Journal:  Clin Rheum Dis       Date:  1985-12

9.  Serum IgG and IgM rheumatoid factors by solid phase radioimmunoassay. A comparison between adult and juvenile rheumatoid arthritis.

Authors:  R Wernick; J J LoSpalluto; C W Fink; M Ziff
Journal:  Arthritis Rheum       Date:  1981-12

10.  A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months.

Authors:  J M Kremer; J K Lee
Journal:  Arthritis Rheum       Date:  1988-05
View more
  3 in total

1.  Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis.

Authors:  A Spadaro; V Riccieri; A Sili Scavalli; F Sensi; E Taccari; A Zoppini
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

2.  Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis.

Authors:  Georgios Christopoulos; V Christopoulou; J G Routsias; A Babionitakis; C Antoniadis; G Vaiopoulos
Journal:  Clin Rheumatol       Date:  2016-10-08       Impact factor: 2.980

Review 3.  Molecular action of methotrexate in inflammatory diseases.

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Arthritis Res       Date:  2002-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.